Trial Outcomes & Findings for Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients (NCT NCT02939079)

NCT ID: NCT02939079

Last Updated: 2019-05-14

Results Overview

5 cc of venous blood is taken from patients and are kept in test tubes without ethylenediaminetetraacetic acid (EDTA). Test tubes are kept one hour immobilized so that clotted blood and serum are separated. Then, the serum is divided into four samples of 0.5 cc for immunologic testing of all primary outcomes. Immunologic testing is performed by sandwich ELISA method using Diaclone ® kits (made in France) and according to manufacturer's instructions.

Recruitment status

COMPLETED

Study phase

PHASE2/PHASE3

Target enrollment

50 participants

Primary outcome timeframe

Baseline

Results posted on

2019-05-14

Participant Flow

The recruitment period started on April 2015. 74 patients were screened initially and 50 of them were recruited. All the patients were recruited from the neurology department of Kashani hospital, Isfahan, iran. They were patients referred to the neurology department (multiple sclerosis clinic) for evaluation and treatment.

After recruitment, no medication was prescribed for the patients for two months as the wash-out period. Then patients were assigned to study groups.

Participant milestones

Participant milestones
Measure
Fingolimod and Fish Oil
Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Fish Oil: produced by Zahravi ® Pharm Company in Iran
Fingolimod and Placebo
Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Placebo (for Fish Oil): placebo capsules to mimic Fish Oil 1 g capsules
Overall Study
STARTED
25
25
Overall Study
COMPLETED
21
20
Overall Study
NOT COMPLETED
4
5

Reasons for withdrawal

Reasons for withdrawal
Measure
Fingolimod and Fish Oil
Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Fish Oil: produced by Zahravi ® Pharm Company in Iran
Fingolimod and Placebo
Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Placebo (for Fish Oil): placebo capsules to mimic Fish Oil 1 g capsules
Overall Study
Adverse Event
2
1
Overall Study
Lost to Follow-up
0
2
Overall Study
Protocol Violation
1
0
Overall Study
Withdrawal by Subject
0
1
Overall Study
relapse during the study
1
1

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Fingolimod and Fish Oil
n=21 Participants
Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Fish Oil: produced by Zahravi ® Pharm Company in Iran
Fingolimod and Placebo
n=20 Participants
Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Placebo (for Fish Oil): placebo capsules to mimic Fish Oil 1 g capsules
Total
n=41 Participants
Total of all reporting groups
Age, Continuous
35.19 years
STANDARD_DEVIATION 9.97 • n=21 Participants
31.40 years
STANDARD_DEVIATION 8.41 • n=20 Participants
33.34 years
STANDARD_DEVIATION 9.21 • n=41 Participants
Sex: Female, Male
Female
13 Participants
n=21 Participants
16 Participants
n=20 Participants
29 Participants
n=41 Participants
Sex: Female, Male
Male
8 Participants
n=21 Participants
4 Participants
n=20 Participants
12 Participants
n=41 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
Iran
21 participants
n=21 Participants
20 participants
n=20 Participants
41 participants
n=41 Participants
Dietary habits, Categorical (seafood meals per month)
0-1 meals per month
19 Participants
n=21 Participants
18 Participants
n=20 Participants
37 Participants
n=41 Participants
Dietary habits, Categorical (seafood meals per month)
2-4 meals per month
2 Participants
n=21 Participants
2 Participants
n=20 Participants
4 Participants
n=41 Participants
Dietary habits, Categorical (seafood meals per month)
>4 meals per month
0 Participants
n=21 Participants
0 Participants
n=20 Participants
0 Participants
n=41 Participants
EDSS
3.10 units on a scale
STANDARD_DEVIATION 1.28 • n=21 Participants
2.55 units on a scale
STANDARD_DEVIATION 1.38 • n=20 Participants
2.83 units on a scale
STANDARD_DEVIATION 1.33 • n=41 Participants

PRIMARY outcome

Timeframe: Baseline

Population: Per-protocol analysis

5 cc of venous blood is taken from patients and are kept in test tubes without ethylenediaminetetraacetic acid (EDTA). Test tubes are kept one hour immobilized so that clotted blood and serum are separated. Then, the serum is divided into four samples of 0.5 cc for immunologic testing of all primary outcomes. Immunologic testing is performed by sandwich ELISA method using Diaclone ® kits (made in France) and according to manufacturer's instructions.

Outcome measures

Outcome measures
Measure
Fingolimod and Fish Oil
n=21 Participants
Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Fish Oil: produced by Zahravi ® Pharm Company in Iran
Fingolimod and Placebo
n=20 Participants
Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Placebo (for Fish Oil): placebo capsules to mimic Fish Oil 1 g capsules
Serum Level of TNF-α
37.16 Pg/ml
Standard Deviation 92.74
28.79 Pg/ml
Standard Deviation 47.46

PRIMARY outcome

Timeframe: Baseline

5 cc of venous blood is taken from patients and are kept in test tubes without EDTA. Test tubes are kept one hour immobilized so that clotted blood and serum are separated. Then, the serum is divided into four samples of 0.5 cc for immunologic testing of all primary outcomes. Immunologic testing is performed by sandwich ELISA method using Diaclone ® kits (made in France) and according to manufacturer's instructions.

Outcome measures

Outcome measures
Measure
Fingolimod and Fish Oil
n=21 Participants
Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Fish Oil: produced by Zahravi ® Pharm Company in Iran
Fingolimod and Placebo
n=20 Participants
Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Placebo (for Fish Oil): placebo capsules to mimic Fish Oil 1 g capsules
Serum Level of IL1b
13.76 Pg/ml
Standard Deviation 0.74
14 Pg/ml
Standard Deviation 1.03

PRIMARY outcome

Timeframe: Baseline

5 cc of venous blood is taken from patients and are kept in test tubes without EDTA. Test tubes are kept one hour immobilized so that clotted blood and serum are separated. Then, the serum is divided into four samples of 0.5 cc for immunologic testing of all primary outcomes. Immunologic testing is performed by sandwich ELISA method using Diaclone ® kits (made in France) and according to manufacturer's instructions.

Outcome measures

Outcome measures
Measure
Fingolimod and Fish Oil
n=21 Participants
Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Fish Oil: produced by Zahravi ® Pharm Company in Iran
Fingolimod and Placebo
n=20 Participants
Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Placebo (for Fish Oil): placebo capsules to mimic Fish Oil 1 g capsules
Serum Level of IL6
6.19 Pg/ml
Standard Deviation 0.35
6.33 Pg/ml
Standard Deviation 0.58

PRIMARY outcome

Timeframe: Baseline

5 cc of venous blood is taken from patients and are kept in test tubes without EDTA. Test tubes are kept one hour immobilized so that clotted blood and serum are separated. Then, the serum is divided into four samples of 0.5 cc for immunologic testing of all primary outcomes. Immunologic testing is performed by sandwich ELISA method using Diaclone ® kits (made in France) and according to manufacturer's instructions.

Outcome measures

Outcome measures
Measure
Fingolimod and Fish Oil
n=21 Participants
Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Fish Oil: produced by Zahravi ® Pharm Company in Iran
Fingolimod and Placebo
n=20 Participants
Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Placebo (for Fish Oil): placebo capsules to mimic Fish Oil 1 g capsules
Serum Level of IFN-gamma
6.38 Pg/ml
Standard Deviation 1.51
6.98 Pg/ml
Standard Deviation 3.87

PRIMARY outcome

Timeframe: 6 months after intervention

5 cc of venous blood is taken from patients and are kept in test tubes without EDTA. Test tubes are kept one hour immobilized so that clotted blood and serum are separated. Then, the serum is divided into four samples of 0.5 cc for immunologic testing of all primary outcomes. Immunologic testing is performed by sandwich ELISA method using Diaclone ® kits (made in France) and according to manufacturer's instructions.

Outcome measures

Outcome measures
Measure
Fingolimod and Fish Oil
n=21 Participants
Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Fish Oil: produced by Zahravi ® Pharm Company in Iran
Fingolimod and Placebo
n=20 Participants
Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Placebo (for Fish Oil): placebo capsules to mimic Fish Oil 1 g capsules
Serum Level of TNF-α
28.03 Pg/ml
Standard Deviation 60.36
17.18 Pg/ml
Standard Deviation 18.88

PRIMARY outcome

Timeframe: 1 year after intervention

5 cc of venous blood is taken from patients and are kept in test tubes without EDTA. Test tubes are kept one hour immobilized so that clotted blood and serum are separated. Then, the serum is divided into four samples of 0.5 cc for immunologic testing of all primary outcomes. Immunologic testing is performed by sandwich ELISA method using Diaclone ® kits (made in France) and according to manufacturer's instructions.

Outcome measures

Outcome measures
Measure
Fingolimod and Fish Oil
n=21 Participants
Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Fish Oil: produced by Zahravi ® Pharm Company in Iran
Fingolimod and Placebo
n=20 Participants
Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Placebo (for Fish Oil): placebo capsules to mimic Fish Oil 1 g capsules
Serum Level of TNF-α
21.20 Pg/ml
Standard Deviation 36.45
16.47 Pg/ml
Standard Deviation 16.64

PRIMARY outcome

Timeframe: 6 months after intervention

5 cc of venous blood is taken from patients and are kept in test tubes without EDTA. Test tubes are kept one hour immobilized so that clotted blood and serum are separated. Then, the serum is divided into four samples of 0.5 cc for immunologic testing of all primary outcomes. Immunologic testing is performed by sandwich ELISA method using Diaclone ® kits (made in France) and according to manufacturer's instructions.

Outcome measures

Outcome measures
Measure
Fingolimod and Fish Oil
n=21 Participants
Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Fish Oil: produced by Zahravi ® Pharm Company in Iran
Fingolimod and Placebo
n=20 Participants
Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Placebo (for Fish Oil): placebo capsules to mimic Fish Oil 1 g capsules
Serum Level of IL1b
13.61 Pg/ml
Standard Deviation 0.58
13.47 Pg/ml
Standard Deviation 0.74

PRIMARY outcome

Timeframe: 1 year after intervention

5 cc of venous blood is taken from patients and are kept in test tubes without EDTA. Test tubes are kept one hour immobilized so that clotted blood and serum are separated. Then, the serum is divided into four samples of 0.5 cc for immunologic testing of all primary outcomes. Immunologic testing is performed by sandwich ELISA method using Diaclone ® kits (made in France) and according to manufacturer's instructions.

Outcome measures

Outcome measures
Measure
Fingolimod and Fish Oil
n=21 Participants
Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Fish Oil: produced by Zahravi ® Pharm Company in Iran
Fingolimod and Placebo
n=20 Participants
Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Placebo (for Fish Oil): placebo capsules to mimic Fish Oil 1 g capsules
Serum Level of IL1b
13.17 Pg/ml
Standard Deviation 0.52
13.15 Pg/ml
Standard Deviation 0.61

PRIMARY outcome

Timeframe: 6 months after intervention

5 cc of venous blood is taken from patients and are kept in test tubes without EDTA. Test tubes are kept one hour immobilized so that clotted blood and serum are separated. Then, the serum is divided into four samples of 0.5 cc for immunologic testing of all primary outcomes. Immunologic testing is performed by sandwich ELISA method using Diaclone ® kits (made in France) and according to manufacturer's instructions.

Outcome measures

Outcome measures
Measure
Fingolimod and Fish Oil
n=21 Participants
Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Fish Oil: produced by Zahravi ® Pharm Company in Iran
Fingolimod and Placebo
n=20 Participants
Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Placebo (for Fish Oil): placebo capsules to mimic Fish Oil 1 g capsules
Serum Level of IL6
6.65 Pg/ml
Standard Deviation 2.11
6.17 Pg/ml
Standard Deviation 0.71

PRIMARY outcome

Timeframe: 1 year after intervention

5 cc of venous blood is taken from patients and are kept in test tubes without EDTA. Test tubes are kept one hour immobilized so that clotted blood and serum are separated. Then, the serum is divided into four samples of 0.5 cc for immunologic testing of all primary outcomes. Immunologic testing is performed by sandwich ELISA method using Diaclone ® kits (made in France) and according to manufacturer's instructions.

Outcome measures

Outcome measures
Measure
Fingolimod and Fish Oil
n=21 Participants
Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Fish Oil: produced by Zahravi ® Pharm Company in Iran
Fingolimod and Placebo
n=20 Participants
Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Placebo (for Fish Oil): placebo capsules to mimic Fish Oil 1 g capsules
Serum Level of IL6
6.17 Pg/ml
Standard Deviation 0.76
6.05 Pg/ml
Standard Deviation 0.47

PRIMARY outcome

Timeframe: 6 months after intervention

5 cc of venous blood is taken from patients and are kept in test tubes without EDTA. Test tubes are kept one hour immobilized so that clotted blood and serum are separated. Then, the serum is divided into four samples of 0.5 cc for immunologic testing of all primary outcomes. Immunologic testing is performed by sandwich ELISA method using Diaclone ® kits (made in France) and according to manufacturer's instructions.

Outcome measures

Outcome measures
Measure
Fingolimod and Fish Oil
n=21 Participants
Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Fish Oil: produced by Zahravi ® Pharm Company in Iran
Fingolimod and Placebo
n=20 Participants
Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Placebo (for Fish Oil): placebo capsules to mimic Fish Oil 1 g capsules
Serum Level of IFN-gamma
5.71 Pg/ml
Standard Deviation 0.57
6.37 Pg/ml
Standard Deviation 1.77

PRIMARY outcome

Timeframe: 1 year after intervention

5 cc of venous blood is taken from patients and are kept in test tubes without EDTA. Test tubes are kept one hour immobilized so that clotted blood and serum are separated. Then, the serum is divided into four samples of 0.5 cc for immunologic testing of all primary outcomes. Immunologic testing is performed by sandwich ELISA method using Diaclone ® kits (made in France) and according to manufacturer's instructions.

Outcome measures

Outcome measures
Measure
Fingolimod and Fish Oil
n=21 Participants
Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Fish Oil: produced by Zahravi ® Pharm Company in Iran
Fingolimod and Placebo
n=20 Participants
Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Placebo (for Fish Oil): placebo capsules to mimic Fish Oil 1 g capsules
Serum Level of IFN-gamma
5.92 Pg/ml
Standard Deviation 1.31
5.99 Pg/ml
Standard Deviation 0.84

Adverse Events

Fingolimod and Fish Oil

Serious events: 2 serious events
Other events: 0 other events
Deaths: 0 deaths

Fingolimod and Placebo

Serious events: 2 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Fingolimod and Fish Oil
n=25 participants at risk
Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Fish Oil: produced by Zahravi ® Pharm Company in Iran
Fingolimod and Placebo
n=25 participants at risk
Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year. Fingolimod: Produced by Osveh ® Pharm Company in Iran Placebo (for Fish Oil): placebo capsules to mimic Fish Oil 1 g capsules
Cardiac disorders
Hypotension and bradycardia
8.0%
2/25 • Number of events 2 • Patients were evaluated in the study for one year and were observed for adverse events during this period.
Adverse events were collected through follow up phone calls and visits.
8.0%
2/25 • Number of events 2 • Patients were evaluated in the study for one year and were observed for adverse events during this period.
Adverse events were collected through follow up phone calls and visits.

Other adverse events

Adverse event data not reported

Additional Information

Dr. Vahid Shaygannejad

Isfahan University of Medical Sciences

Phone: +98 913 313 3550

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place